gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Mucin and cadherin like

MUCDHL, gp100, Mu-protocadherin
cell adhesion molecule which may be involved in regulation of branching morphogenesis [RGD, Feb 2006] (from NCBI)
Top mentioned proteins: gp100, MART-1, tyrosinase, CAN, Artemis
Papers using MUCDHL antibodies
Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma
Economou James S et al., In Journal of Hematology & Oncology, 2005
... )-restricted epitope of gp100 (25-33) presented on the surface of B16 melanoma, and OTII TCR transgenic mice whose transgenic receptor ...
Mesenchymal–epithelial interactions in the skin
Hearing Vincent J. et al., In The Journal of Cell Biology, 2002
... ), αPEP13h for gp100 (1:4,000 dilution; Virador et al., 2001), and β-catenin (1:50 dilution; Cell Signaling Technology) ...
Papers on MUCDHL
Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells.
de Vries et al., Amsterdam, Netherlands. In Clin Cancer Res, Jan 2016
EXPERIMENTAL DESIGN Fourteen stage IV melanoma patients, without previous systemic treatment for metastatic disease, received autologous CD1c+ myeloid DCs, activated by only brief (16h) ex vivo culture and loaded with tumor associated antigens of tyrosinase and gp100.
Desmoplastic Melanoma: An Updated Immunohistochemical Analysis of 40 cases with a Proposal for an Additional Panel of Stains for Diagnosis.
Suster et al., Milwaukee, United States. In J Cutan Pathol, Jan 2016
The purpose of this study was to analyze 40 cases of DM with a comprehensive panel of immunohistochemical markers (KBA.62, p16, Ezrin, WT-1, MITF-1, SOX-10, CD117, SOX-2, Nestin, PNL2, p75, MART-1, gp100 and S100p) to obtain a more complete understanding of the potential use of these antibodies in the diagnosis of DM.
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
Bahjat et al., Portland, United States. In Cancer Res, Jan 2016
We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4%) randomly assigned to receive ipilimumab or gp100 peptide vaccine.
Co-potentiation of antigen recognition: A mechanism to boost weak T cell responses and provide immunotherapy in vivo.
Gil et al., Rochester, United States. In Sci Adv, Oct 2015
We identified Mono-7D6-Fab, which biophysically altered TCR/CD3 when bound and functionally enhanced immune reactivity to several weak antigens in vitro, including a gp100-derived peptide associated with melanoma.
Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature.
Yosipovitch et al., Jackson, United States. In Acta Derm Venereol, Feb 2015
MART-1/2, gp100, tyrosinase) have been presented on the surface of both normal and malignant melanocytes and mediate the development of MAL after cytotoxic CD8+ T cells attack both cell types.
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.
Tiwari et al., Valhalla, United States. In J Cancer, 2014
Expression of MAAs such as MART-1 and gp100 is modulated by the MAPK signaling pathway, which is often deregulated in melanoma.
Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.
Overwijk et al., Houston, United States. In Int J Biochem Cell Biol, 2014
The vaccination site eventually became a T cell graveyard where T cells responded to chronically released gp100 peptide by releasing cytokines, including interferon-γ (IFN-γ), which in turn upregulated Fas ligand (FasL) on host cells, causing apoptosis of Fas(+) T cells.
Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
Rosenberg et al., Bethesda, United States. In Cancer Control, 2013
Pilot trials using TCR-engineered cells against melanoma-associated antigens MART-1 and gp100 and the cancer-testis antigen NY-ESO-1 have shown clinical responses in patients with melanoma.
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.
Overwijk et al., Houston, United States. In Nat Med, 2013
To understand why cancer vaccine-induced T cells often do not eradicate tumors, we studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA), which is commonly used in clinical cancer vaccine trials.
[Antibody therapies for melanoma].
Okuyama et al., Chinju, South Korea. In Nihon Rinsho, 2012
Although 10 mg/kg of ipilimumab showed 10-15% of objective response, phase 3 study of ipilimumab with gp100 vaccination or with dacarbazine showed prolonged survival.
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.
Wolchok, New York City, United States. In Ann Oncol, 2012
Among the pretreated patients, ipilimumab monotherapy significantly improved median OS (Hazard ratio (HR): 0.66, P = 0.003) from 6.4 months in gp100 vaccine controls to 10.1 months.
Cdx2 controls expression of the protocadherin Mucdhl, an inhibitor of growth and β-catenin activity in colon cancer cells.
Gross et al., Strasbourg, France. In Gastroenterology, 2012
The transcription factor Cdx2 activates expression of the protocadherin Mucdhl, which interacts with beta-catenin and regulates activities of colon cancer cells.
Polymorphism at the mucin-like protocadherin gene influences susceptibility to gallstone disease.
Juo et al., Kao-hsiung, Taiwan. In Clin Chim Acta, 2011
The MUPCDH genetic polymorphism rs3758650 was considered a genetic marker to predict symptomatic Gallstone disease subjects.
Down-regulation of μ-protocadherin expression is a common event in colorectal carcinogenesis.
Grande et al., Reggio nell'Emilia, Italy. In Hum Pathol, 2011
Our data consequently suggest that down-regulation of mu-protocadherin expression is a common event in colorectal carcinogenesis and might therefore play an important role in this pathologic process.
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Hwu et al., Goshen, United States. In N Engl J Med, 2011
In a previous phase 2 study, patients with metastatic melanoma receiving high-dose interleukin-2 plus the gp100:209-217(210M) peptide vaccine had a higher rate of response than the rate that is expected among patients who are treated with interleukin-2 alone.
Improved survival with ipilimumab in patients with metastatic melanoma.
Urba et al., Boston, United States. In N Engl J Med, 2010
In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
Rehm et al., Charlottesville, United States. In J Clin Oncol, 2008
Source proteins for these peptides include MAGE proteins, MART-1/MelanA, gp100, and tyrosinase.
Biallelic expression of HRAS and MUCDHL in human and mouse.
Tycko et al., New York City, United States. In Hum Genet, 2003
MUCDHL genes are biallelically expressed in multiple fetal and adult tissues both in humans and in mice
Identification and expression analysis of the human mu-protocadherin gene in fetal and adult kidneys.
Warburton et al., New York City, United States. In Am J Physiol Renal Physiol, 2002
identifed the human mu-protocadherin ortholog and examined its expression in the developing kidney
share on facebooktweetadd +1mail to friends